09:30 AM EST, 12/18/2024 (MT Newswires) -- Novo Holdings, the controlling shareholder of Novo Nordisk ( NVO ) , has completed its $16.5 billion, all-cash acquisition of contract development and manufacturing firm Catalent (CLCT), the companies said on Wednesday.

Under terms of the transaction, Catalent shareholders received $63.50 in cash for each of their share, a premium of around 47.5% to the volume-weighted average price of the stock prior to the deal being announced in early February.

Catalent shares stopped trading on Wednesday and are being delisted from the New York Stock Exchange, the companies said.